Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 1/20 | 0.31 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.31 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 2/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tibo SCHEMBL8013680 | 1.00 | GRIN2D (0.31) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Tibo SCHEMBL29623959 | 1.00 | GRIN2D (0.31) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Hydrochloric Acid SCHEMBL9523974 | 0.89 | HTR1A (0.32) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL599870 | 0.83 | HTR1A (0.46) | HTR1ADRD2 | |
| SCHEMBL4062423 | 0.83 | HTR1A (0.46) | HTR1ADRD2 | |
| SCHEMBL29624058 | 0.83 | HTR1A (0.46) | HTR1ADRD2 | |
| SCHEMBL7896188 | 0.82 | SIGMAR1 (0.30) | — | |
| Tivirapine SCHEMBL3145162 | 0.79 | HTR1A (0.31) | HTR1ADRD2 | |
| Tivirapine SCHEMBL377308 | 0.79 | HTR1A (0.31) | HTR1ADRD2 | |
| Tivirapine SCHEMBL8844208 | 0.78 | HTR1A (0.31) | HTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 215 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119039316-A | Breviane spiro diterpenoid compounds derived from deep sea fungi, and preparation method and application thereof | 自然资源部第三海洋研究所 | 2024-11-29 | — | — | CN | claimed |
| CN-118978502-A | DMOA-source mixed terpenoid in deep sea fungi, and preparation method, composition and application thereof | 自然资源部第三海洋研究所 | 2024-11-19 | — | — | CN | claimed |
| CN-114507139-B | Cyclopropane compound, preparation method thereof and application of cyclopropane compound in resisting influenza virus | 自然资源部第三海洋研究所 | 2023-04-28 | — | — | CN | claimed |
| CN-114507139-A | Cyclopropane compound, preparation method thereof and application of cyclopropane compound to anti-influenza virus | 自然资源部第三海洋研究所 | 2022-05-17 | — | — | CN | claimed |
| CN-114292272-A | Nucleoside compound and application thereof | 南方科技大学 | 2022-04-08 | — | — | CN | claimed |
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PHARMACIA CORPORATION | 2005-02-03 | — | — | US | claimed |
| US-6673830-B2 | COMPOUNDS FROM PLANTS OF THE GENUS CALOPHYLLUM, METHODS OF EXTRACTION AND USE AS TREATMENT FOR HUMAN IMMUMODEFICIENCY VIRUS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN SERVICES | 2004-01-06 | — | — | US | claimed |
| EP-0666744-A1 | USE OF BHAP COMPOUNDS IN COMBINATION WITH OTHER NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR THE TREATMENT OF HIV INFECTION | THE UPJOHN COMPANY (US) | 1995-08-16 | — | — | EP | claimed |
| US-5371079-A | Administering to inhibit replication of HIV-1 in human cells | JANSSEN PHARMACEUTICA N.V. (BE) | 1994-12-06 | — | — | US | claimed |
| WO-1994009781-A1 | USE OF BHAP COMPOUNDS IN COMBINATION WITH OTHER NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR THE TREATMENT OF HIV INFECTION | THE UPJOHN COMPANY (US) | 1994-05-11 | — | — | WO | claimed |
| EP-0384522-B1 | Antiviral tetrahydroimidazo[1,4]benzodiazepin-2-thiones | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-01-13 | — | — | EP | claimed |
| CN-122059926-A | Heterocyclic degradation determinants for target protein degradation | C4医药公司 | 2026-05-19 | — | — | CN | disclosed |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | UNIV YALE (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4342543-B1 | TERT-BUTYL 2-(4-PHENYL-6H-THIENO[3,2-F][1,2,4]TRIAZOLO[4,3-A] [1,4]DIAZEPIN-6-YL) ACETATE DERIVATIVES AS BROMODOMAIN BRD4 INHIBITORS FOR TREATING CANCER | HOFFMANN LA ROCHE (CH) | 2026-04-29 | — | — | EP | disclosed |
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| WO-1994028000-A1 | CALANOLIDE AND RELATED ANTIVIRAL COMPOUNDS, COMPOSITIONS, AND USES THEREOF | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1994-12-08 | — | — | WO | disclosed |
| US-5371079-A | Administering to inhibit replication of HIV-1 in human cells | JANSSEN PHARMACEUTICA N.V. (BE) | 1994-12-06 | — | — | US | disclosed |
| US-5371079-A | Administering to inhibit replication of HIV-1 in human cells | JANSSEN PHARMACEUTICA N.V. (BE) | 1994-12-06 | — | — | US | disclosed |
| WO-1994009781-A1 | USE OF BHAP COMPOUNDS IN COMBINATION WITH OTHER NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR THE TREATMENT OF HIV INFECTION | THE UPJOHN COMPANY (US) | 1994-05-11 | — | — | WO | disclosed |
| US-5270464-A | Anti-HIV-1 tetrahydroimidazo[1,4]benzodiazepin-2-(thi) ones | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | NEDD4, UBE3A, UBE3C | GRIN2D 2899/4885GRIN3B 1899/4885GRIN1 1068/4885 |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, VHL, ADRM1 | GRIN2D 4735/4885GRIN3B 4658/4885GRIN1 4587/4885 |
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PTGS2, PTGS1, PTGES2 | GRIN2D 3217/4885GRIN3B 2048/4885GRIN1 2442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.